Medicare Rx Coverage Rules Could Compromise Beneficiary Safety – Blues Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
Some drug classes with a two-drug coverage requirement could force plans to cover a product they consider to be less safe than another in the class, Excellus BlueCross BlueShield exec says. An internal analysis finds drug costs will rise at least 3.5% if U.S. Pharmacopeia’s “recommended subdivisions” are turned into classes.